Today Rising Biosciences, Inc. (OTC:RBII) Rising Biosciences, Inc. filed a “Attorney Letter with Respect to Current Information – RBII Attorney Opinion with Respect Current Information” , with the intention of going OTC Pink current. This comes after the company released its latest CBD offering by announcing a CBD Only Variant of Cannophen(TM) to Begin Pilot Production, which will be coming to Market Soon according to the company.
According to the CEO,
We are nearing the final stages of releasing CBD only Cannophen for distribution, Stated Mr. Hall, I have just received the UPC symbols for both the oral capsules and vape cartridges for our CBD only variant of Cannophen . The first production run is done and initial samples are being sent to the lab for testing. Our debut run back in June tested at a full 25mg CBD per capsule, so we anticipate similar results for this batch of our CBD only variant. We are highly gratified to announce that CBD only Cannophen will be coming to the market soon, both for what it will mean for our shareholders and for how it will advance our purpose in combating the opioid crisis in the Midwest and beyond. At the Rising Biosciences offices, we have been buzzing like a beehive in recent days working on new developments. We anticipate releasing more great news very soon. Please check out and follow our new Twitter account: https://twitter.com/RisingBioscien1 About Rising Biosciences, Inc.
This comes after the company announced a major acquisition, detailed below.
Rising Biosciences, Inc. (OTC: RBII) is pleased to announce the recent acquisition of Southern Northern Behavioral Health, Inc. (SNB Health) a growing substance abuse treatment company, as a wholly owned subsidiary. In conjunction with the acquisition, Rising Biosciences has signed a contract to purchase a 40,000 square foot former recreation facility that will be renovated for use as a behavioral health inpatient center for the purpose of treating all types of substance abuse including opioid addiction, alcohol abuse and related mental health issues.